Innate and adaptive immunity: the Yin and Yang of celiac disease
Corresponding Author
Bana Jabri
Department of Pathology, Medicine and Pediatrics, University of Chicago, Chicago, IL, USA.
* Bana Jabri, MD Department of Pathology, Medicine and Pediatrics, University of Chicago 5841 South Maryland Avenue – MC 1089 Chicago, IL 60637, USA Tel.: +1 773 834 8670 Fax: +1 773 702 3701 E-mail: [email protected]Search for more papers by this authorDonald D. Kasarda
US Department of Agriculture, Agricultural Research Service, Western Regional Research Center, Albany, CA, USA.
Search for more papers by this authorPeter H. R. Green
Department of Medicine, Columbia University, College of Physicians and Surgeons, NY, USA.
Search for more papers by this authorCorresponding Author
Bana Jabri
Department of Pathology, Medicine and Pediatrics, University of Chicago, Chicago, IL, USA.
* Bana Jabri, MD Department of Pathology, Medicine and Pediatrics, University of Chicago 5841 South Maryland Avenue – MC 1089 Chicago, IL 60637, USA Tel.: +1 773 834 8670 Fax: +1 773 702 3701 E-mail: [email protected]Search for more papers by this authorDonald D. Kasarda
US Department of Agriculture, Agricultural Research Service, Western Regional Research Center, Albany, CA, USA.
Search for more papers by this authorPeter H. R. Green
Department of Medicine, Columbia University, College of Physicians and Surgeons, NY, USA.
Search for more papers by this authorAbstract
Summary: Celiac disease is a multigenetic complex inflammatory disorder with an autoimmune component, induced by gluten, a protein found in wheat. It is a unique human disease model to dissect the innate and adaptive immune mechanisms underlying T-cell-mediated tissue destruction and the development of T-cell lymphoma in conditions of chronic T-cell activation.
References
- 1 Anderson DM. History of celiac disease. J Am Diet Assoc 1959; 35: 1158–1162.
- 2 Louka AS, Sollid LM. HLA in coeliac disease: unravelling the complex genetics of a complex disorder. Tissue Antigens 2003; 61: 105–117.
- 3 Lundin KE, Scott H, Fausa O, Thorsby E, Sollid LM. T cells from the small intestinal mucosa of a DR4, DQ7/DR4, DQ8 celiac disease patient preferentially recognize gliadin when presented by DQ8. Hum Immunol 1994; 41: 285–291.
- 4 Lundin KE, et al. Gliadin-specific, HLA-DQ(alpha 1*0501,beta 1*0201) restricted T cells isolated from the small intestinal mucosa of celiac disease patients. J Exp Med 1993; 178: 187–196.
- 5 Dieterich W, et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997; 3: 797–801.
- 6
Molberg O, et al.
T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase.
Eur J Immunol
2001; 31:
1317–1323.
10.1002/1521-4141(200105)31:5<1317::AID-IMMU1317>3.0.CO;2-I CAS PubMed Web of Science® Google Scholar
- 7 Van De Wal Y, et al. Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. J Immunol 1998; 161: 1585–1588.
- 8 Falchuk ZM, Gebhard RL, Sessoms C, Strober W. An in vitro model of gluten-sensitive enteropathy. Effect of gliadin on intestinal epithelial cells of patients with gluten-sensitive enteropathy in organ culture. J Clin Invest 1974; 53: 487–500.
- 9 Howdle PD, Ciclitira PJ, Simpson FG, Losowsky MS. Are all gliadins toxic in coeliac disease? An in vitro study of alpha, beta, gamma, and w gliadins. Scand J Gastroenterol 1984; 19: 41–47.
- 10 Loft DE, et al. Studies of intestinal lymphoid tissue. XII. Epithelial lymphocyte and mucosal responses to rectal gluten challenge in celiac sprue. Gastroenterology 1989; 97: 29–37.
- 11 Sturgess R, et al. Wheat peptide challenge in coeliac disease. Lancet 1994; 343: 758–761.
- 12 De Ritis G, Auricchio S, Jones HW, Lew EJ, Bernardin JE, Kasarda DD. In vitro (organ culture) studies of the toxicity of specific A-gliadin peptides in celiac disease. Gastroenterology 1988; 94: 41–49.
- 13 Shidrawi RG, Day P, Przemioslo R, Ellis HJ, Nelufer JM, Ciclitira PJ. In vitro toxicity of gluten peptides in coeliac disease assessed by organ culture. Scand J Gastroenterol 1995; 30: 758–763.
- 14
Marsh MN, et al.
In vivo activity of peptides 31–43, 44–55, 56–68 of αgliadin in gluten sensitive enteropathy (GSE).
Gastroenterology
1995; 108: A871.
10.1016/0016-5085(95)27792-7 Google Scholar
- 15 Maiuri L, et al. Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. Lancet 2003; 362: 30–37.
- 16 Hue S, et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 2004; 21: 367–377.
- 17 Green PH, Jabri B. Coeliac disease. Lancet 2003; 362: 1419.
- 18 Jabri B, et al. Selective expansion of intraepithelial lymphocytes expressing the HLA-E-specific natural killer receptor CD94 in celiac disease. Gastroenterology 2000; 118: 867–879.
- 19 Meresse B, et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 2004; 21: 357–366.
- 20 Maiuri L, Ciacci C, Auricchio S, Brown V, Quaratino S, Londei M. Interleukin 15 mediates epithelial changes in celiac disease. Gastroenterology 2000; 119: 996–1006.
- 21 Mention JJ, et al. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology 2003; 125: 730–745.
- 22 Marsh MN. Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity (‘celiac sprue’). Gastroenterology 1992; 102: 330–354.
- 23 Tursi A, Brandimarte G, Giorgetti GM. Prevalence of antitissue transglutaminase antibodies in different degrees of intestinal damage in celiac disease. J Clin Gastroenterol 2003; 36: 219–221.
- 24 Abrams JA, Diamond B, Rotterdam H, Green PH. Seronegative celiac disease: increased prevalence with lesser degrees of villous atrophy. Dig Dis Sci 2004; 49: 546–550.
- 25 Rostom A, et al. The diagnostic accuracy of serologic tests for celiac disease: a systematic review. Gastroenterology 2005; 128: S38–S46.
- 26 Ventura A, Magazu G, Gerarduzzi T, Greco L. Coeliac disease and the risk of autoimmune disorders. Gut 2002; 51: 897; author reply 897–898.
- 27 Sategna Guidetti C, Solerio E, Scaglione N, Aimo G, Mengozzi G. Duration of gluten exposure in adult coeliac disease does not correlate with the risk for autoimmune disorders. Gut 2001; 49: 502–505.
- 28 Green PH, Jabri B. Celiac disease and other precursors to small-bowel malignancy. Gastroenterol Clin North Am 2002; 31: 625–639.
- 29 Catassi C, Bearzi I, Holmes GK. Association of celiac disease and intestinal lymphomas and other cancers. Gastroenterology 2005; 128: S79–S86.
- 30 Fairley N, Mackie F. The clinical and biochemical syndrome in lymphadenoma and allied diseases involving the mesenteric lymph glands. Br Med J 1937; 1: 375–380.
- 31 O'Farelly C, et al. Humoral response to wheat protein in patients with coeliac disease and enteropathy associated T cell lymphoma. Br Med J 1986; 293: 908–910.
- 32 Spencer J, MacDonald TT, Diss TC, Walker-Smith JA, Ciclitira PJ, Isaacson PG. Changes in intraepithelial lymphocyte subpopulations in coeliac disease and enteropathy associated T cell lymphoma (malignant histiocytosis of the intestine). Gut 1989; 30: 339–346.
- 33 Stein H, Dienemann D, Sperling M, Zeitz M, Riecken EO. Identification of a T cell lymphoma category derived from intestinal-mucosa-associated T cells. Lancet 1988; 2: 1053–1054.
- 34 Bevan S, et al. Contribution of the MHC region to the familial risk of coeliac disease. J Med Genet 1999; 36: 687–690.
- 35 Petronzelli F, et al. Genetic contribution of the HLA region to the familial clustering of coeliac disease. Ann Hum Genet 1997; 61: 307–317.
- 36 Risch N. Assessing the role of HLA-linked and unlinked determinants of disease. Am J Hum Genet 1987; 40: 1–14.
- 37 Greco L, et al. The first large population based twin study of coeliac disease. Gut 2002; 50: 624–628.
- 38 Vader W, et al. The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses. Proc Natl Acad Sci USA 2003; 100: 12390–12395.
- 39 Ploski R, Ek J, Thorsby E, Sollid LM. On the HLA-DQ(alpha 1*0501,beta 1*0201)-associated susceptibility in celiac disease: a possible gene dosage effect of DQB1*0201. Tissue Antigens 1993; 41: 173–177.
- 40 Gonzalez S, et al. Association of MHC class I related gene B (MICB) to celiac disease. Am J Gastroenterol 2004; 99: 676–680.
- 41 Bolognesi E, et al. Additional factor in some HLA DR3/DQ2 haplotypes confers a fourfold increased genetic risk of celiac disease. Tissue Antigens 2003; 61: 308–316.
- 42 Martin-Pagola A, et al. MICA response to gliadin in intestinal mucosa from celiac patients. Immunogenetics 2004; 56: 549–554.
- 43 McManus R, et al. Association of celiac disease with microsatellite polymorphisms close to the tumor necrosis factor genes. Hum Immunol 1996; 45: 24–31.
- 44 McManus R, Wilson AG, Mansfield J, Weir DG, Duff GW, Kelleher D. TNF2, a polymorphism of the tumour necrosis-alpha gene promoter, is a component of the celiac disease major histocompatibility complex haplotype. Eur J Immunol 1996; 26: 2113–2118.
- 45 Walker-Smith JA. IgA deficiency and coeliac disease. Lancet 1971; 2: 430–431.
- 46 Kalha I, Sellin JH. Common variable immunodeficiency and the gastrointestinal tract. Curr Gastroenterol Rep 2004; 6: 377–383.
- 47 Dabbas M, et al. Pancreatitis in children on long-term parenteral nutrition. Transplant Proc 1996; 28: 2782.
- 48 Djilali-Saiah I, Schmitz J, Harfouch-Hammoud E, Mougenot JF, Bach JF, Caillat-Zucman S. CTLA-4 gene polymorphism is associated with predisposition to coeliac disease. Gut 1998; 43: 187–189.
- 49 Holopainen P, et al. CD28/CTLA4 gene region on chromosome 2q33 confers genetic susceptibility to celiac disease. A linkage and family-based association study. Tissue Antigens 1999; 53: 470–475.
- 50 Popat S, et al. Analysis of the CTLA4 gene in Swedish coeliac disease patients. Scand J Gastroenterol 2002; 37: 28–31.
- 51 Clot F, et al. Linkage and association study of the CTLA-4 region in coeliac disease for Italian and Tunisian populations. Tissue Antigens 1999; 54: 527–530.
- 52 Greco L, et al. Existence of a genetic risk factor on chromosome 5q in Italian coeliac disease families. Ann Hum Genet 2001; 65: 35–41.
- 53 Naluai AT, et al. Genome-wide linkage analysis of Scandinavian affected sib-pairs supports presence of susceptibility loci for celiac disease on chromosomes 5 and 11. Eur J Hum Genet 2001; 9: 938–944.
- 54 Liu J, et al. Genomewide linkage analysis of celiac disease in Finnish families. Am J Hum Genet 2002; 70: 51–59.
- 55 Van Belzen MJ, et al. A major non-HLA locus in celiac disease maps to chromosome 19. Gastroenterology 2003; 125: 1032–1041.
- 56 Holopainen P, Mustalahti K, Uimari P, Collin P, Maki M, Partanen J. Candidate gene regions and genetic heterogeneity in gluten sensitivity. Gut 2001; 48: 696–701.
- 57 Sampson HA. Update on food allergy. J Allergy Clin Immunol 2004; 113: 805–819; quiz, 820.
- 58 Sollid LM. Coeliac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol 2002; 2: 647–655.
- 59 Arentz-Hansen H, et al. The molecular basis for oat intolerance in patients with celiac disease. Plos Medical 2004; 1: e1.
- 60 Ciclitira PJ, Evans DJ, Fagg NL, Lennox ES, Dowling RH. Clinical testing of gliadin fractions in coeliac patients. Clin Sci (Lond) 1984; 66: 357–364.
- 61 Shan L, et al. Structural basis for gluten intolerance in celiac sprue. Science 2002; 297: 2275–2279.
- 62 Ensari A, Marsh MN, Moriarty KJ, Moore CM, Fido RJ, Tatham AS. Studies in vivo of omega-gliadins in gluten sensitivity (coeliac sprue disease). Clin Sci (Lond) 1998; 95: 419–424.
- 63 Arentz-Hansen H, et al. The intestinal T cell response to alpha-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J Exp Med 2000; 191: 603–612.
- 64 Anderson RP, Degano P, Godkin AJ, Jewell DP, Hill AV. In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nat Med 2000; 6: 337–342.
- 65 Vader LW, et al. Specificity of tissue transglutaminase explains cereal toxicity in celiac disease. J Exp Med 2002; 195: 643–649.
- 66 Jensen K, et al. Gliadin-specific T cell responses in peripheral blood of healthy individuals involve T cells restricted by the coeliac disease associated DQ2 heterodimer. Scand J Immunol 1995; 42: 166–170.
- 67 Catassi C, et al. The coeliac iceberg in Italy. A multicentre antigliadin antibodies screening for coeliac disease in school-age subjects. Acta Paediatr Suppl 1996; 412: 29–35.
- 68 Catassi C, et al. Coeliac disease in the year 2000: exploring the iceberg. Lancet 1994; 343: 200–203.
- 69 Bendelac A, Carnaud C, Boitard C, Bach JF. Syngeneic transfer of autoimmune diabetes from diabetic NOD mice to healthy neonates. Requirement for both L3T4+ and Lyt-2+ T cells. J Exp Med 1987; 166: 823–832.
- 70 Ogasawara K, et al. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 2004; 20: 757–767.
- 71 Wahab PJ, Crusius JB, Meijer JW, Mulder CJ. Gluten challenge in borderline gluten-sensitive enteropathy. Am J Gastroenterol 2001; 96: 1464–1469.
- 72 Sollid LM, Molberg O, McAdam S, Lundin KE. Autoantibodies in coeliac disease: tissue transglutaminase – guilt by association? Gut 1997; 41: 851–852.
- 73 Bruce SE, Bjarnason I, Peters TJ. Human jejunal transglutaminase: demonstration of activity, enzyme kinetics and substrate specificity with special relation to gliadin and coeliac disease. Clin Sci (Lond) 1985; 68: 573–579.
- 74 Molberg O, et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease (published erratum appears in Nat Med 1998;4:974). Nat Med 1998; 4: 713–717.
- 75 Griffin M, Casadio R, Bergamini CM. Transglutaminases: nature's biological glues. Biochem J 2002; 368: 377–396.
- 76 Caputo I, D'Amato A, Troncone R, Auricchio S, Esposito C. Transglutaminase 2 in celiac disease: minireview article. Amino Acids 2004; 26: 381–386.
- 77 Vader W, et al. The gluten response in children with celiac disease is directed toward multiple gliadin and glutenin peptides. Gastroenterology 2002; 122: 1729–1737.
- 78 Kim CY, Quarsten H, Bergseng E, Khosla C, Sollid LM. Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc Natl Acad Sci USA 2004; 101: 4175–4179.
- 79 Gjertsen HA, Sollid LM, Ek J, Thorsby E, Lundin KE. T cells from the peripheral blood of coeliac disease patients recognize gluten antigens when presented by HLA-DR-DQ, or -DP molecules. Scand J Immunol 1994; 39: 567–574.
- 80 Molberg O, et al. HLA restriction patterns of gliadin- and astrovirus-specific CD4+ T cells isolated in parallel from the small intestine of celiac disease patients. Tissue Antigens 1998; 52: 407–415.
- 81 Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419: 734–738.
- 82 Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci USA 2003; 100: 9452–9457.
- 83 Dulphy N, et al. Functional modulation of expanded CD8+ synovial fluid T cells by NK cell receptor expression in HLA-B27-associated reactive arthritis. Int Immunol 2002; 14: 471–479.
- 84 Roberts AI, et al. NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J Immunol 2001; 167: 5527–5530.
- 85 Speiser DE, et al. In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. J Exp Med 1999; 190: 775–782.
- 86 Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23: 225–274.
- 87 McMahon CW, Raulet DH. Expression and function of NK cell receptors in CD8+ T cells. Curr Opin Immunol 2001; 13: 465–470.
- 88 Vivier E, Anfossi N. Inhibitory NK-cell receptors on T cells: witness of the past, actors of the future. Nat Rev Immunol 2004; 4: 190–198.
- 89 Forsberg G, Hernell O, Melgar S, Israelsson A, Hammarstrom S, Hammarstrom ML. Paradoxical co-expression of proinflammatory and down-regulatory cytokines in intestinal T cells in childhood celiac disease. Gastroenterology 2002; 123: 667–678.
- 90 Oberhuber G, Vogelsang H, Stolte M, Muthenthaler S, Kummer AJ, Radaszkiewicz T. Evidence that intestinal intraepithelial lymphocytes are activated cytotoxic T cells in celiac disease but not in giardiasis. Am J Pathol 1996; 148: 1351–1357.
- 91 Isaacson PG. Relation between cryptic intestinal lymphoma and refractory sprue. Lancet 2000; 356: 178–179.
- 92 Green PH, Jabri B. Coeliac disease. Lancet 2003; 362: 383–391.
- 93 Kutlu T, Brousse N, Rambaud C, Le Deist F, Schmitz J, Cerf-Bensussan N. Numbers of T cell receptor (TCR) alpha beta+ but not of TcR gamma delta+ intraepithelial lymphocytes correlate with the grade of villous atrophy in coeliac patients on a long term normal diet. Gut 1993; 34: 208–214.
- 94 Sturgess RP, Loft D, Kontakou M, Crowe P, Marsh MN, Ciclitira PJ. Rectal epithelial gamma/delta T-lymphocyte responses to local gluten challenge in coeliac disease. Scand J Gastroenterol 1993; 28: 760–762.
- 95 Maiuri L, et al. IL-15 drives the specific migration of CD94+ and TCR-gammadelta+ intraepithelial lymphocytes in organ cultures of treated celiac patients. Am J Gastroenterol 2001; 96: 150–156.
- 96 Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood 2001; 97: 14–32.
- 97 Boismenu R, Havran WL. Modulation of epithelial cell growth by intraepithelial gamma delta T cells. Science 1994; 266: 1253–1255.
- 98 Jameson J, et al. A role for skin gammadelta T cells in wound repair. Science 2002; 296: 747–749.
- 99 Rust C, Pena S, Kluin P, Koning F. Gamma delta T cells in coeliac disease. Res Immunol 1990; 141: 668–671.
- 100 Trier JS, Falchuk ZM, Carey MC, Schreiber DS. Celiac sprue and refractory sprue. Gastroenterology 1978; 75: 307–316.
- 101 Cellier C, et al. Abnormal intestinal intraepithelial lymphocytes in refractory sprue. Gastroenterology 1998; 114: 471–481.
- 102 Cellier C, et al. Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma. French Coeliac Disease Study Group. Lancet 2000; 356: 203–208.
- 103 Carbonnel F, et al. Are complicated forms of celiac disease cryptic T-cell lymphomas? Blood 1998; 92: 3879–3886.
- 104 Bagdi E, Diss TC, Munson P, Isaacson PG. Mucosal intra-epithelial lymphocytes in enteropathy-associated T-cell lymphoma, ulcerative jejunitis, and refractory celiac disease constitute a neoplastic population. Blood 1999; 94: 260–264.
- 105 Ohmori H, Hikida M. Expression and function of recombination activating genes in mature B cells. Crit Rev Immunol 1998; 18: 221–235.
- 106 Jabri B, et al. TCR specificity dictates CD94/NKG2A expression by human CTL. Immunity 2002; 17: 487–499.
- 107 Fehniger TA, et al. Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J Exp Med 2001; 193: 219–231.
- 108 Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301–305.
- 109 Medzhitov R, Janeway CA Jr. Decoding the patterns of self and nonself by the innate immune system. Science 2002; 296: 298–300.
- 110 Tuckova L, et al. Activation of macrophages by gliadin fragments: isolation and characterization of active peptide. J Leukoc Biol 2002; 71: 625–631.
- 111 Tuckova L, Flegelova Z, Tlaskalova-Hogenova H, Zidek Z. Activation of macrophages by food antigens: enhancing effect of gluten on nitric oxide and cytokine production. J Leukoc Biol 2000; 67: 312–318.
- 112 Nilsen EM, et al. Gluten induces an intestinal cytokine response strongly dominated by interferon gamma in patients with celiac disease. Gastroenterology 1998; 115: 551–563.
- 113 Cammarota G, Cuoco L, Cianci R, Pandolfi F, Gasbarrini G. Onset of coeliac disease during treatment with interferon for chronic hepatitis C. Lancet 2000; 356: 1494–1495.
- 114
Monteleone G,
Pender SL,
Wathen NC,
MacDonald TT.
Interferon-alpha drives T cell-mediated immunopathology in the intestine.
Eur J Immunol
2001; 31:
2247–2255.
10.1002/1521-4141(200108)31:8<2247::AID-IMMU2247>3.0.CO;2-4 CAS PubMed Web of Science® Google Scholar
- 115 Durante-Mangoni E, et al. Silent celiac disease in chronic hepatitis C: impact of interferon treatment on the disease onset and clinical outcome. J Clin Gastroenterol 2004; 38: 901–905.